CA3157954A1 - Pharmaceutical composition, comprising recombinant stabilized galectin 9 protein, for prevention or treatment of rheumatoid arthritis and bone disease - Google Patents

Pharmaceutical composition, comprising recombinant stabilized galectin 9 protein, for prevention or treatment of rheumatoid arthritis and bone disease Download PDF

Info

Publication number
CA3157954A1
CA3157954A1 CA3157954A CA3157954A CA3157954A1 CA 3157954 A1 CA3157954 A1 CA 3157954A1 CA 3157954 A CA3157954 A CA 3157954A CA 3157954 A CA3157954 A CA 3157954A CA 3157954 A1 CA3157954 A1 CA 3157954A1
Authority
CA
Canada
Prior art keywords
bone
sease
gal
ecti
protei
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3157954A
Other languages
English (en)
French (fr)
Inventor
Dong Ho Song
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gbiologics Inc
Original Assignee
Gbiologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gbiologics Inc filed Critical Gbiologics Inc
Priority claimed from PCT/KR2020/015782 external-priority patent/WO2021096217A1/ko
Publication of CA3157954A1 publication Critical patent/CA3157954A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3157954A 2019-11-11 2020-11-11 Pharmaceutical composition, comprising recombinant stabilized galectin 9 protein, for prevention or treatment of rheumatoid arthritis and bone disease Pending CA3157954A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20190143752 2019-11-11
KR10-2019-0143752 2019-11-11
PCT/KR2020/015782 WO2021096217A1 (ko) 2019-11-11 2020-11-11 재조합 안정화 갈렉틴 9 단백질을 포함하는 류마티스 관절염 및 골질환 예방 또는 치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
CA3157954A1 true CA3157954A1 (en) 2021-05-20

Family

ID=76142932

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3157954A Pending CA3157954A1 (en) 2019-11-11 2020-11-11 Pharmaceutical composition, comprising recombinant stabilized galectin 9 protein, for prevention or treatment of rheumatoid arthritis and bone disease

Country Status (4)

Country Link
KR (1) KR102267413B1 (ko)
CN (1) CN115605217A (ko)
BR (1) BR112022005782A2 (ko)
CA (1) CA3157954A1 (ko)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8268324B2 (en) * 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
JP5888761B2 (ja) 2012-11-20 2016-03-22 国立大学法人 香川大学 ガレクチン９の改変タンパク質

Also Published As

Publication number Publication date
CN115605217A (zh) 2023-01-13
KR20210056927A (ko) 2021-05-20
KR102267413B1 (ko) 2021-06-21
BR112022005782A2 (pt) 2022-10-11

Similar Documents

Publication Publication Date Title
CA3131052A1 (en) Pharmaceutical composition for subcutaneous injection comprising human hyaluronidase ph20 variant and drug
CN101072875B (zh) 新型癌抗原肽及其用途
US6759234B1 (en) Compositions and methods for administering to humans, peptides capable of down regulating an antigen specific immune response
JP2000511561A (ja) 肥満症の処置のためのｃｎｔｆ（毛様体神経成長因子）受容体アクティベーターの使用
Sonntag et al. Moderate caloric restriction alters the subcellular distribution of somatostatin mRNA and increases growth hormone pulse amplitude in aged animals
MX2010014078A (es) Composiciones y metodos para inmunogenecidad mejorada de somatostatina.
KR101184833B1 (ko) Ｈｃｇ 절편들을 포함하는 점막 및 경구 투여용 조성물
AU674697B2 (en) Use of specific binding molecules in potentiating IGF-I activity
KR20130094337A (ko) 개량형 이듀로네이트-2-설파타제 및 이의 용도
US10351598B2 (en) Peptide with anti-obesity and anti-diabetic efficacy and use thereof
JP2002502369A (ja) 胃腸管上部の機能を強化する方法
US20170204151A1 (en) Mesenchymal Stem Cells Expressing Biomarkers that Predict the Effectiveness of Mesenchymal Stem Cells for Treating Diseases and Disorders
CA3157954A1 (en) Pharmaceutical composition, comprising recombinant stabilized galectin 9 protein, for prevention or treatment of rheumatoid arthritis and bone disease
CN102060910B (zh) 锌转运蛋白8的hla-a＊0201限制性ctl表位及其应用
CN115850377A (zh) 基于nras基因q61k突变的肿瘤新抗原多肽及其应用
KR20000053216A (ko) 펩티드 면역 요법 치료제
CN110946988A (zh) 含短肽的组合物及短肽用于制备抑制或减缓虾过敏反应的药物组合物的用途
WO2005004789A2 (fr) Methode de traitement de maladies s'accompagnant d'alterations de la composition qualitative ou quantitative de l'adn extracellulaire du sang
BR112019014406A2 (pt) métodos de tratar esclerose múltipla usando células t autólogas
JPH10505356A (ja) ヒトへの投与のための組成物および方法、抗原特異的免疫応答のダウンレギュレーションを行うことが可能なペプチド
CA2568384A1 (en) Immune response suppressor and treatment of multiple sclerosis
CN101166540A (zh) Gpr39基因在哺乳动物中枢神经系统的功能及其应用
JPH10337189A (ja) 新規化合物
AU759409B2 (en) Preventives and/or remedies for obesity
CN101602793B (zh) 用于预防和/或治疗类风湿性关节炎的免疫调节多肽及其应用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510

EEER Examination request

Effective date: 20220510